What are the latest funding news in the femtech market? (September 2026)
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
Femtech companies announced 12 qualifying financings worth approximately $64.5M from 18 June through 31 August 2026.
Channel Medsystems accounted for $30M, making menstrual and gynecological treatment the largest funded category in this selection.
The deal flow also covered preterm birth, uterine research, fertility care, menopause therapeutics, vaginal diagnostics, pelvic health and women-focused virtual care.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- Channel Medsystems represented about 47% of disclosed capital in this femtech funding selection, showing that commercial medical devices can still attract much larger checks than most early-stage women’s health startups.
- Nine of the 12 financings were below $5M, which indicates that recent femtech market activity remained concentrated in seed, launch and clinical-validation rounds rather than late-stage scale-ups.
- Only about $2.2M of the $64.5M total came from non-dilutive public grants, suggesting that equity financing remained the main funding route even for reproductive-health research infrastructure.
- Eight companies were primarily focused on the United States, reinforcing the country’s role as the main commercial and financing hub for emerging femtech companies.
- Diagnostics, data and clinical infrastructure appeared across Juno Bio, Xella Health, Ovum and Opal Therapeutics, showing that investors are backing better measurement as well as new care products.
- Pregnancy, childbirth and pelvic health attracted capital at several maturity levels, from Daré Bioscience’s preclinical preterm-birth program to Materna Medical’s clinical-commercial device portfolio.
- Investor and valuation disclosure remained limited across the femtech market, especially in seed and angel rounds, making announced round size more visible than private-company pricing.
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Summary table of the latest funding deals in the femtech market as of September 2026
We define the femtech market as technology-enabled products and services that address women’s reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women (e.g., breast and gynecological cancers).
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women’s biology, care pathways, or life stages.
You can also read our detailed analysis to understand how funding activity in the femtech market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the femtech market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| June Health | 18 June 2026 | About $1.75M | Early-stage venture round | Women’s Virtual Care & Clinical Navigation |
| Ovum | 22 June 2026 | About $2.6M | Seed | Women’s Clinical Navigation & Health Data |
| Xella Health | 24 June 2026 | $4.7M | Angel & Pre-seed | Women’s Diagnostics & Virtual Care |
| Materna Medical | 30 June 2026 | $5M | Series B3 | Pregnancy, Childbirth & Pelvic Health |
| Mila | 1 July 2026 | $2.5M | Pre-seed | Sexual Health & Intimate Care |
| Juno Bio | 16 July 2026 | $3.8M | Early-stage venture round | Vaginal Health & Reproductive Diagnostics |
| Estrigenix | 22 July 2026 | $2M | Series Seed first close | Menopause & Hormone Therapeutics |
| American Baby Company | 23 July 2026 | $4M | Seed | Fertility Clinics & Assisted Reproduction |
| DITTO | 28 July 2026 | $6M | Seed | Menstrual Health |
| Opal Therapeutics | 6 August 2026 | $1.25M | NSF SBIR Phase II | Reproductive Health Research Tools |
| Channel Medsystems | 20 August 2026 | $30M | Series C | Menstrual Health & Gynecological Devices |
| Daré Bioscience | 31 August 2026 | About $0.91M | Non-dilutive NIH funding | Pregnancy & Reproductive Therapeutics |
All the latest funding deals during in the femtech market as of September 2026
Daré Bioscience received about $0.91M in NIH funding in August 2026 for preterm-birth research.
When was it?
Daré Bioscience announced the NIH award on 31 August 2026.
Who are they?
Daré Bioscience is a clinical-stage biotech developing therapies for women’s health, including a program intended to prevent idiopathic preterm birth.
Geographical focus?
Daré Bioscience is based in the United States and develops products for the US women’s-health market.
Why do we include them in the femtech market?
Daré Bioscience belongs in the femtech market because DARE-PTB2 targets pregnancy care and the prevention of preterm birth.
What is the company stage?
Daré Bioscience is a clinical-stage biotech, while DARE-PTB2 remains in early preclinical development.
How much did they raise?
Daré Bioscience received approximately $0.91M in non-dilutive funding for this program.
What round is it?
Daré Bioscience received an NIH award rather than an equity financing round.
Why did they raise?
Daré Bioscience raised the grant funding to advance preclinical pharmacokinetic, safety and toxicity work for DARE-PTB2.
Channel Medsystems raised $30M in August 2026 to expand Cerene commercialization.
When was it?
Channel Medsystems announced the Series C milestone on 20 August 2026.
Who are they?
Channel Medsystems makes the Cerene cryotherapy device, a non-hormonal treatment for heavy menstrual bleeding and dysmenorrhea.
Geographical focus?
Channel Medsystems is based in the United States and is expanding access to Cerene for US patients and providers.
Why do we include them in the femtech market?
Channel Medsystems belongs in the femtech market because Cerene treats female-specific menstrual and gynecological conditions.
What is the company stage?
Channel Medsystems is at the commercial growth stage following the relaunch of its Cerene platform.
How much did they raise?
Channel Medsystems reached $30M in its ongoing Series C financing.
What round is it?
Channel Medsystems raised a Series C led by InnovaHealth Partners.
Why did they raise?
Channel Medsystems raised the capital to grow its commercial team, expand education and awareness, and broaden patient access to Cerene.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
Opal Therapeutics secured $1.25M in August 2026 to expand uterine organoid infrastructure.
When was it?
Opal Therapeutics announced the NSF award on 6 August 2026.
Who are they?
Opal Therapeutics develops uterine organoid models that support reproductive-health drug discovery and diagnostic research.
Geographical focus?
Opal Therapeutics is based in the United States and serves reproductive-health researchers and life-sciences partners.
Why do we include them in the femtech market?
Opal Therapeutics belongs in the femtech market because its research platform is built around uterine biology and women’s reproductive health.
What is the company stage?
Opal Therapeutics is at a pre-commercial research and development stage.
How much did they raise?
Opal Therapeutics received $1.25M in non-dilutive grant funding.
What round is it?
Opal Therapeutics received an NSF SBIR Phase II award rather than a conventional venture round.
Why did they raise?
Opal Therapeutics raised the grant funding to advance uterine organoid technology toward commercial research applications.
DITTO raised $6M in July 2026 to expand menstrual-health research and products.
When was it?
DITTO announced its seed financing on 28 July 2026.
Who are they?
DITTO develops evidence-based supplements and research tools for PMS, PMDD and other menstrual-cycle symptoms.
Geographical focus?
DITTO is Europe-focused and can expand its consumer products and research model across international markets.
Why do we include them in the femtech market?
DITTO belongs in the femtech market because its products and clinical research focus directly on menstrual and cycle health.
What is the company stage?
DITTO is at an early-growth stage with commercial products, an established community and ongoing clinical studies.
How much did they raise?
DITTO raised $6M in this financing.
What round is it?
DITTO raised a seed round led by FoodLabs, with participation from EKA Ventures.
Why did they raise?
DITTO raised the funding to scale research, run larger studies and develop additional evidence-based menstrual-health products.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
American Baby Company raised $4M in July 2026 to open its first fertility clinic.
When was it?
American Baby Company’s financing was announced on 23 July 2026.
Who are they?
American Baby Company is building fertility clinics that offer standardized IVF and egg-freezing care at transparent prices.
Geographical focus?
American Baby Company is focused on the United States, beginning with a clinic in West Palm Beach, Florida.
Why do we include them in the femtech market?
American Baby Company belongs in the femtech market because its care model centers on IVF, egg freezing and reproductive endocrinology.
What is the company stage?
American Baby Company is at the pre-launch and clinic-expansion stage.
How much did they raise?
American Baby Company raised $4M in this round.
What round is it?
American Baby Company raised a seed round led by Wormhole Capital and Tower Research Ventures.
Why did they raise?
American Baby Company raised the capital to open its first clinic, establish laboratory operations and prepare for expansion.
Estrigenix secured a $2M seed first close in July 2026 for menopause therapeutics.
When was it?
Estrigenix announced the first close of its financing on 22 July 2026.
Who are they?
Estrigenix develops selective estrogen receptor-beta therapies for menopause-related neurological and cognitive symptoms.
Geographical focus?
Estrigenix is based in the United States and is developing therapeutics with potential global pharmaceutical applications.
Why do we include them in the femtech market?
Estrigenix belongs in the femtech market because its therapeutic platform targets menopause and hormone-related women’s health needs.
What is the company stage?
Estrigenix is at a preclinical and pre-product stage before human clinical trials.
How much did they raise?
Estrigenix secured a $2M first close.
What round is it?
Estrigenix raised the first close of a Series Seed led by Talents Fund I.
Why did they raise?
Estrigenix raised the funding for preclinical experiments, trial preparation and future pharmaceutical partnerships.
In our femtech market deck, we identify pain points entrepreneurs should prioritize
Juno Bio raised $3.8M in July 2026 while opening a women’s-health sequencing laboratory.
When was it?
Juno Bio announced the financing on 16 July 2026.
Who are they?
Juno Bio uses sequencing and multi-omics to provide clinically actionable vaginal microbiome testing.
Geographical focus?
Juno Bio was founded in the United Kingdom and is commercially focused on the United States, including its Oakland sequencing laboratory.
Why do we include them in the femtech market?
Juno Bio belongs in the femtech market because its platform addresses vaginal health, reproductive health and gynecological conditions.
What is the company stage?
Juno Bio is at an early-commercial growth stage with testing available and a CLIA-certified laboratory in operation.
How much did they raise?
Juno Bio raised $3.8M in this financing.
What round is it?
Juno Bio completed an early-stage venture round, without a consistently disclosed formal series label.
Why did they raise?
Juno Bio raised the capital to scale laboratory operations, broaden testing and provide more actionable results to clinicians.
Mila raised $2.5M in July 2026 to launch women’s intimate-care products.
When was it?
Mila announced its pre-seed round on 1 July 2026.
Who are they?
Mila develops design-led women’s intimate-care products, including a multifunctional device and a hydrating gliding mist.
Geographical focus?
Mila is headquartered in Miami and is building a consumer brand for the United States and international markets.
Why do we include them in the femtech market?
Mila belongs in the femtech market because its portfolio directly addresses women’s sexual health and intimate care.
What is the company stage?
Mila is at the pre-seed and initial-market-entry stage.
How much did they raise?
Mila raised $2.5M in this round.
What round is it?
Mila completed an oversubscribed pre-seed round led by Mensch VC.
Why did they raise?
Mila raised the funding to complete product development, support manufacturing, build its brand and expand distribution.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Materna Medical raised $5M in June 2026 to advance childbirth and pelvic-health devices.
When was it?
Materna Medical announced the financing on 30 June 2026.
Who are they?
Materna Medical develops medical devices designed to reduce pelvic-floor injury during childbirth and support vaginal dilation therapy.
Geographical focus?
Materna Medical is based in the United States and initially serves hospitals, obstetric teams and pelvic-health patients in the country.
Why do we include them in the femtech market?
Materna Medical belongs in the femtech market because its products target childbirth-related pelvic trauma and female pelvic health.
What is the company stage?
Materna Medical is at the late-clinical and early-commercial growth stage.
How much did they raise?
Materna Medical raised $5M in this financing.
What round is it?
Materna Medical described the transaction as a B3 financing, a later extension of its Series B funding.
Why did they raise?
Materna Medical raised the capital to support clinical work, commercialization, manufacturing and access to its cleared device.
Xella Health disclosed $4.7M in June 2026 with the launch of its diagnostics platform.
When was it?
Xella Health disclosed the financing when it launched on 24 June 2026.
Who are they?
Xella Health combines genomic, protein and hormone testing with medical history to create female-specific risk profiles and care plans.
Geographical focus?
Xella Health launched across most US states and is building a national diagnostics and telehealth model.
Why do we include them in the femtech market?
Xella Health belongs in the femtech market because its diagnostics and care pathways are designed around female biology.
What is the company stage?
Xella Health is at the launch and very early-commercial stage.
How much did they raise?
Xella Health disclosed $4.7M in cumulative angel and pre-seed funding.
What round is it?
Xella Health described the capital as angel and pre-seed financing, without a separate amount for each close.
Why did they raise?
Xella Health used the funding to build its testing platform, laboratory infrastructure, telehealth service and initial commercial operations.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Ovum raised about $2.6M in June 2026 to expand its women’s health data platform.
When was it?
Ovum’s A$4M seed financing was first reported on 22 June 2026.
Who are they?
Ovum combines symptoms, reproductive history, medication, wearable data and medical records to help women identify health patterns.
Geographical focus?
Ovum launched in Australia and plans to expand internationally through consumer, employer, insurer and health-organization partnerships.
Why do we include them in the femtech market?
Ovum belongs in the femtech market because its data platform and care-navigation model are built around women’s health histories.
What is the company stage?
Ovum is at an early-growth stage with consumer adoption and institutional partnership activity.
How much did they raise?
Ovum raised A$4M, equivalent to about US$2.6M.
What round is it?
Ovum raised a seed round led by Admiralty Capital Group.
Why did they raise?
Ovum raised the funding to improve its AI, pursue regulatory clearances, expand internationally and grow its longitudinal health dataset.
June Health raised about $1.75M in June 2026 to scale women’s virtual care.
When was it?
June Health announced the financing on 18 June 2026.
Who are they?
June Health provides AI-assisted care navigation and virtual access to clinicians across fertility, hormonal health, menopause and sexual health.
Geographical focus?
June Health focuses on Canada and distributes its platform through employers, insurers, benefits providers and affinity organizations.
Why do we include them in the femtech market?
June Health belongs in the femtech market because its care model is designed around women’s health pathways and life stages.
What is the company stage?
June Health is at an early-commercial stage with a live platform and institutional distribution partners.
How much did they raise?
June Health raised C$2.4M, equivalent to about US$1.75M.
What round is it?
June Health completed an early-stage venture round without a publicly disclosed formal series label.
Why did they raise?
June Health raised the capital to strengthen its AI and data infrastructure, expand care delivery and add distribution partners.
Related blog posts
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
- How strong is fundraising in the femtech market right now?
